Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Chigenovo Co. Ltd. oversees a portfolio within the Biotechnology & Pharmaceuticals technology area, currently facing 5 pending office actions. These matters are assigned to 5 distinct examiners, ensuring that each active case is reviewed by a different 1 individual. This lack of examiner concentration suggests that the company's prosecution success is not tied to 1 person's review style.
The active cases are situated within 4 distinct art units, reflecting a range of technical subject matter. YU, DAVID TUYANG is the busiest examiner, holding 1 pending office action. With 5 total pending actions distributed across 4 art units, the company must navigate various administrative and technical standards. For a practitioner, this requires a flexible strategy that addresses the specific requirements of 4 different art units and the individual preferences of 5 examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
| DUNN, LINDSAY MICHELLE | 1 | 80.0% | +0.0% |
| WARD, AARON DUREL | 1 | — | — |
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18360742 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | DUNN, LINDSAY MICHELLE | 26d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18571164 | PRPF31 VARIANT AND USES THEREOF | YU, DAVID TUYANG | — |
| 18248523 | NUCLEIC ACID MOLECULE FOR TREATING BIETTI CRYSTALLINE DYSTROPHY AND USE THEREOF | WARD, AARON DUREL | — |
| 17756996 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | JADHAO, SAMADHAN JAISING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17756996 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | JADHAO, SAMADHAN JAISING | — |
| 17996786 | RHO-ADRP GENE EDITING-BASED METHODS AND COMPOSITIONS | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1636 | 1 |
| 1672 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18571164 | PRPF31 VARIANT AND USES THEREOF | YU, DAVID TUYANG | — | §103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18360742 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | DUNN, LINDSAY MICHELLE | 1644 | §103DP | Non-Final OA | 26d | Pending | Jul 27, 2023 |
| 18248523 | NUCLEIC ACID MOLECULE FOR TREATING BIETTI CRYSTALLINE DYSTROPHY AND USE THEREOF | WARD, AARON DUREL | 1636 | §102§103§112 | Non-Final OA | — | Pending | Apr 10, 2023 |
| 17756996 | USE OF CYP4V2 AND RDCVF IN THE MANUFACTURE OF MEDICAMENT | JADHAO, SAMADHAN JAISING | 1672 | §101§103§112DPOther | Non-Final OA | — | Pending | Jan 24, 2023 |
| 17996786 | RHO-ADRP GENE EDITING-BASED METHODS AND COMPOSITIONS | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial